Ibopamine
File:Ibopamine.svg | |
Systematic (IUPAC) name | |
---|---|
5-[2-(methylamino)ethyl]-2-[(2-methylpropanoyl)oxy]phenyl 2-methylpropanoate
|
|
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Identifiers | |
CAS Number | 66195-31-1 |
ATC code | C01CA16 (WHO) S01FB03 |
PubChem | CID: 68555 |
ChemSpider | 61829 |
UNII | 8ZCA2I2L11 |
KEGG | D04488 |
Chemical data | |
Formula | C17H25NO4 |
Molecular mass | 307.385 g/mol |
|
|
|
|
(what is this?) (verify) |
Ibopamine is a sympathomimetic drug, designed as a prodrug of epinine, used in ophthalmology.[1] It induces mydriasis.[2] It also has been investigated for use in the treatment of congestive heart failure.[3]
It acts on D1[4][5] and α receptors as an agonist.[6]
Ibopamine was first prepared by Casagrande and co-workers.[7]
Instilled at 2% concentration, ibopamine exhibits several functions at ocular level such as pre- and post-operative mydriatic activity, D1 dopaminergic activity, etc.[8]
Pharmacokinetics
Due to the esterases existed in the aqueous humour and ocular tissues,
ibopamine can be rapidly hydrolysed to epinine which is the active molecule responsible for the mydriatic effect.[9] The epinine, an analogue of dopamine, can stimulate dopamine receptors and to a lesser degree adrenergic receptors.[10] Thus it is believed that epinine is the pharmacologically active moiety. It has been shown that the half-life of ibopamine is short to about 2 minutes in the aqueous humour owing to the fast hydrolysis.[11] So ibopamine can not be found in the aqueous humor after instillation.
Pharmacodynamics
After being hydrolysed to epinine, ibopamine is able to stimulate the alpha-adrenergic and D1 dopaminergic receptors, thereby exhibiting mydriatic effects.[12] In some randomized clinical trials, the D1 dopaminergic activity of ibopamine led to an increased production of aqueous humour and intraocular pressure (IOP) in primary open-angle glaucoma (POAG) patients.[13]
Toxicology
At systemic and local levels, ibopamine has been proved to be of low toxicity. It is well-tolerated since no obvious changes to the haematological and behavioural parameters have been observed after administration.[14] Ibopamine eye drop at 2% concentration, containing 1 mg of the compound, did not show any significant systemic side-effects and tachyphylaxis phenomena whereas the oral dosage is higher than 400 mg per day.[15]
Clinical Use
A fast and short-lasting mydriasis can be induced by ibopamine without systemic side-effects.
See also
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- Pages with broken file links
- Chemical articles having calculated molecular weight overwritten
- Articles with changed InChI identifier
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- Alpha-adrenergic agonists
- D1-receptor agonists
- Phenethylamines
- Isobutyrates